作者
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C Montefiori, Bethany Girard, Darin K Edwards, Jing Feng, Honghong Zhou, Lindsey R Baden, Jacqueline M Miller, Rituparna Das
发表日期
2022/10/6
期刊
New England Journal of Medicine
卷号
387
期号
14
页码范围
1279-1291
出版商
Massachusetts Medical Society
简介
Background
The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.
Methods
In this ongoing, phase 2–3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster. We administered mRNA-1273.214 or mRNA-1273 as a second booster in adults who had previously received a two-dose (100-μg) primary series and first booster (50-μg) dose of mRNA-1273 (≥3 months earlier). The primary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 28 days after the booster dose.
Results
Interim results are presented. Sequential groups of participants received 50 μg of mRNA-1273.214 (437 participants) or mRNA-1273 (377 participants) as a second booster …
学术搜索中的文章
S Chalkias, C Harper, K Vrbicky, SR Walsh, B Essink… - New England Journal of Medicine, 2022